Literature DB >> 3277745

"Sandwich"-type immunoassay of carcinoembryonic antigen in patients receiving murine monoclonal antibodies for diagnosis and therapy.

F J Primus1, E A Kelley, H J Hansen, D M Goldenberg.   

Abstract

Measurements of carcinoembryonic antigen (CEA) in blood increased dramatically in some patients who were receiving injections of monoclonal antibody. CEA titers were measured with a monoclonal antibody-based double-determinant enzyme immunoassay in which untreated plasma specimens were diluted with an equal volume of buffer containing mouse serum. Increasing CEA titers were accompanied by the appearance and coincident increase in titers of human antibody against mouse Ig (HAMA). Adsorption of these sera with solid-phase anti-human IgG or Protein A restored antigen titers to pretreatment values; evidently the serum factor eliciting false-positive CEA titers was most probably HAMA. Neither addition of undiluted mouse serum to the assay mixture nor pretreatment by heating plasma specimens to 70 degrees C effectively abolished HAMA interference. By contrast, protein precipitation with polyethylene glycol (130 g/L) or heating plasma samples to 90 degrees C eliminated false-positive titers caused by HAMA, but did not reduce authentic CEA titers.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3277745

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  14 in total

1.  [Human anti-murine immunoglobulin antibodies as disturbing factors in TSH determination].

Authors:  G Horneff; W Becker; F Wolf; J R Kalden; G R Burmester
Journal:  Klin Wochenschr       Date:  1991-03-18

2.  Anti-cytokine autoantibodies in autoimmune diseases.

Authors:  Giuseppe Cappellano; Elisabetta Orilieri; Abiy D Woldetsadik; Elena Boggio; Maria F Soluri; Cristoforo Comi; Daniele Sblattero; Annalisa Chiocchetti; Umberto Dianzani
Journal:  Am J Clin Exp Immunol       Date:  2012-11-15

3.  Chemotherapy of a patient because of spuriously elevated alpha-fetoprotein levels. Identification of the responsible factor.

Authors:  N Dahlmann; J H Hartlapp
Journal:  Klin Wochenschr       Date:  1989-04-03

4.  Comparative biological properties of a recombinant chimeric anti-carcinoma mAb and a recombinant aglycosylated variant.

Authors:  P H Hand; B Calvo; D Milenic; T Yokota; M Finch; P Snoy; K Garmestani; O Gansow; J Schlom; S V Kashmiri
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

5.  Effect of folic Acid on hematological changes in methionine-induced hyperhomocysteinemia in rats.

Authors:  M N Ansari; G K Nigam; Uma Bhandari
Journal:  Indian J Pharm Sci       Date:  2009-05       Impact factor: 0.975

6.  Idiotypic cascades after injection of the monoclonal antibody OC125. A study in a mouse model.

Authors:  B C Schultes; J Reinsberg; U Wagner; H Schlebusch; H Richter; D Krebs; H J Biersack
Journal:  Cell Biophys       Date:  1994

Review 7.  Monoclonal antibodies in the management of carcinoma patients.

Authors:  M Roselli; C U Casciani; F Guadagni; O Buonomo; B Iorio; A Diodati; V Vittorini; J W Greiner; D Colcher; J Schlom
Journal:  Med Oncol Tumor Pharmacother       Date:  1991

8.  Evaluation of human carcinoembryonic-antigen (CEA)-transduced and non-transduced murine tumors as potential targets for anti-CEA therapies.

Authors:  P H Hand; P F Robbins; M L Salgaller; D J Poole; J Schlom
Journal:  Cancer Immunol Immunother       Date:  1993       Impact factor: 6.968

9.  Hormonal and histological study on irregular genital bleeding in patients with endometriosis during treatment with dienogest, a novel progestational therapeutic agent.

Authors:  Minoru Irahara; Tasuku Harada; Mikio Momoeda; Yuji Tamaki
Journal:  Reprod Med Biol       Date:  2007-11-07

10.  Detecting tau in serum of transgenic animal models after tau immunotherapy treatment.

Authors:  Cristina d'Abramo; Christopher M Acker; Joel B Schachter; Giuseppe Terracina; Xiaohai Wang; Stefanie K Forest; Peter Davies
Journal:  Neurobiol Aging       Date:  2015-10-21       Impact factor: 4.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.